October 27, 2015
11 am to 12 pm EDT

Sponsored by

Webinar Description:

The use of next generation sequencing for clinical applications is growing rapidly and the use of NGS panels is, in some areas, becoming standard of care. While panels can be highly informative from a broad perspective, it is not guaranteed that the particular SNP or insertion/ deletion of interest will be present. When a specific targeted therapy is under evaluation and a single gene is of primary interest, there is a strong rationale for developing a NGS assay specifically for that gene. In this seminar we will present details on the development and implementation of a clinical NGS assay for TP53 which is being used routinely for clinical trial stratification.

Learning Objectives:

  • The process of developing, validating and implementing a clinical NGS assay
  • The issues and considerations in the development of such an assay
  • How NGS clinical testing works in a central lab
  • The long term potential of NGS as a companion diagnostic


Dr. Leeona Galligan: Head of Laboratory Operations – Almac Diagnostics

Dr. Galligan (PhD, FRCPath) has worked for over 15 years in the field of translational molecular oncology and holds the post of Head of Laboratory Operations at Almac Diagnostics where she has overall responsibility for all laboratory based technologies and services supporting Almac Diagnostics’ biomarker discovery, development and delivery.

Prior to joining Almac in 2009, Dr Galligan obtained a PhD in molecular haematology from Trinity College Dublin. She subsequently completed a postdoctoral fellowship on the molecular mechanisms of drug resistance in colorectal cancer at Queen’s University Belfast and has completed a 4 year training programme in specialist haemato-oncology laboratory services. She maintains registration with the UK Health and Care Professions Council as a Clinical Scientist and has been awarded Fellowship of the Royal College of Pathologists (FRCPath) through examination in haemato-oncology and laboratory management.

Michael Sloan: VP of Business Development - Almac

Michael Sloan is VP of Business Development for Almac Diagnostics since 2005. He has full responsibility for the overall management of the company’s business development activities and driving the growth of the company.

Michael has held senior business development and management roles in the biotech and medical device sector for over 20 years in both start up and multinational companies. His previous experience includes Managing Director for BSN Medical UK, Smith and Nephew and Beiersdorf JV and Executive Director for Amtec Medical Ltd.

Cost: No cost!

Schedule conflict? Register and you'll receive a copy of the recording